Biotech grants in Poland

Scheduled

Funds three €5–7M projects that make cancer control more equitable, effective and cost-aware for patients and families.

Scheduled

Funds two €12M projects using living labs to remediate carcinogenic soils and trace cancer risks through people, food, water and air.

Scheduled

Funds €8–10M procurer consortia to bring affordable cancer technologies, devices and medicines from tender to patient benefit.

Scheduled

Funds one €3M coordination action that helps cancer charities and funders improve quality of life for young survivors across Europe.

Scheduled

Funds two €6M projects that use biotechnology to purify captured carbon and turn it into sustainable feedstock for industrial products.

Scheduled

Funds two €5M projects to use biotechnology to recycle complex plastics into high-value products at pilot scale across industrial value chains.

Scheduled

Funds €6M projects that turn bio-waste and secondary raw materials into safe, circular products, materials and value chains.

Scheduled

Funds €7–10M projects that advance living-cell bio-printing from laboratory proof toward regenerative medicine.

Scheduled

Funds a €3M coordination action that benchmarks emerging industrial bio-based systems for cleaner, circular and more competitive European value chains.

Scheduled

Funds three €4M research projects that replace hazardous biocidal actives with safer bio-based substances for wood and mosquito control.

Scheduled

Funds a European community and roadmap for trustworthy frontier AI models in healthcare.

Scheduled

Funds two €7–8M innovation projects that move food-system microbiome products from validated testing toward reliable EU-market scale-up.

Scheduled

Funds two projects to use livestock microbiomes for healthier animals, lower antimicrobial use and safer, more sustainable One Health systems.

Scheduled

Funds early-stage European deep-tech firms developing evidence-ready prototypes and proof-of-concept solutions.

Between cycles

Funds research consortia developing biotechnology-based interventions, biomarkers or non-animal test methods that target the root causes of age-related disease.

Between cycles

Funds late stage deep tech start ups and small businesses with combined non dilutive and growth support across technology fields.

Between cycles

Invests in European deep-tech scale-up ventures with momentum needing capital for commercial expansion.

Between cycles

Invests in scale-up ventures in digital, clean technology, and biotechnology through equity to accelerate commercialization pathways.

Between cycles

Funds a pilot lab where AI and automation run safer, faster and more reproducible food-science experiments.

Between cycles

Funds two €1.5–2.5M actions that give European startups and SMEs simpler access to advanced research and technology infrastructure.

Between cycles

Funds innovative SME-led international R&D consortia through the Eurostars Call 12 grant process.

Between cycles

Funds a research consortium that studies why immune-mediated diseases behave differently when they first strike older adults and hunts for biomarkers to predict them.

Between cycles

Funds advanced innovation projects advancing robotics and physical AI deep-tech initiatives toward scalable outcomes.

Between cycles

Supports ARPA inspired high risk demand driven pilots translating new approach methods into practical deep tech practice.